Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Dow
Queensland Health
Medtronic
Citi
Chinese Patent Office
Boehringer Ingelheim
Cerilliant
Express Scripts
AstraZeneca

Generated: October 17, 2017

DrugPatentWatch Database Preview

Ucb Inc Company Profile

« Back to Dashboard

What is the competitive landscape for UCB INC, and what generic alternatives to UCB INC drugs are available?

UCB INC has forty-eight approved drugs.

There are fifteen US patents protecting UCB INC drugs.

There are three hundred and nineteen patent family members on UCB INC drugs in forty-seven countries and thirty-five supplementary protection certificates in eleven countries.

Summary for Applicant: Ucb Inc

International Patents:319
US Patents:15
Tradenames:32
Ingredients:24
NDAs:48
Drug Master File Entries: (click here to view)1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc
BIPHETAMINE 20
amphetamine resin complex; dextroamphetamine resin complex
CAPSULE, EXTENDED RELEASE;ORAL010093-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ucb Inc
BRIVIACT
brivaracetam
TABLET;ORAL205836-004May 12, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Ucb Inc
NEUPRO
rotigotine
FILM, EXTENDED RELEASE;TRANSDERMAL021829-003May 9, 2007RXYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
BRIVIACT
brivaracetam
TABLET;ORAL205836-001May 12, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Ucb Inc
UNIVASC
moexipril hydrochloride
TABLET;ORAL020312-002Apr 19, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
Ucb Inc
METADATE CD
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021259-002Jun 19, 2003AB2RXYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
VIMPAT
lacosamide
TABLET;ORAL022253-003Oct 28, 2008ABRXYesNo► Subscribe► Subscribe► Subscribe
Ucb Inc
METADATE ER
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE;ORAL089601-001Jun 1, 1988ABRXNoYes► Subscribe► Subscribe► Subscribe
Ucb Inc
LORTAB
acetaminophen; hydrocodone bitartrate
TABLET;ORAL087722-001Jul 9, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ucb Inc
NEUPRO
rotigotine
FILM, EXTENDED RELEASE;TRANSDERMAL021829-005Apr 2, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ucb Inc

Paragraph IV activity for UCB INC drugs

Drugname Dosage Strength Tradename Submissiondate
rotigotine
Extended-release Transdermal Film1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr
NEUPRO
11/26/2013
lacosamide
Oral Solution10 mg/mL
VIMPAT
10/29/2012
lacosamide
Tablets50 mg, 100 mg, 150 mg, and 200 mg
VIMPAT
10/29/2012
levetiracetam
Extended-release Tablets1000 mg
KEPPRA XR
1/7/2011
metformin hydrochloride
Extended-release Capsules40 mg
METADATE CD
3/15/2007
levetiracetam
Tablets1000 mg
KEPPRA
1/24/2007
alprazolam
Orally Disintegrating Tablets0.25 mg, 0.5 mg, 1 mg and 2 mg
NIRAVAM
12/27/2005
metformin hydrochloride
Extended-release Capsules10 mg, 20 mg and 30 mg
METADATE CD
5/13/2005
moexipril hydrochloride and hydrochlorothiazide
Tablets7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg
UNIRETIC
1/15/2004

Non-Orange Book Patents for Ucb Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,217,8262-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
7,863,316Extended release formulation of Levetiracetam► Subscribe
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
8,034,9582-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
6,048,899 Anticonvulsant enantiomeric amino acid derivatives► Subscribe
5,773,475 Anticonvulsant enantiomeric amino acid derivatives► Subscribe
6,858,740 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
6,969,770 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
7,358,2762-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses► Subscribe
6,806,287 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ucb Inc Drugs

Country Document Number Estimated Expiration
Israel150842► Subscribe
Israel165917► Subscribe
European Patent Office1477478► Subscribe
Austria210973► Subscribe
Russian Federation2002118325► Subscribe
Germany59900581► Subscribe
Canada2491366► Subscribe
Australia2001297011► Subscribe
Hong Kong1052695► Subscribe
Norway334187► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ucb Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB06/023United Kingdom► SubscribeSPC/GB06/023: 20070702, EXPIRES: 20210214
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
C0006France► SubscribePRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/470/001 DU 20080829; REGISTRATION NO/DATE AT EEC: EU/1/08/470/001 DU 20080829
00028Netherlands► SubscribePRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C0004France► SubscribePRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
C/GB08/005United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
UBS
Cipla
Moodys
AstraZeneca
McKesson
Queensland Health
Chinese Patent Office
Colorcon
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot